| A recent publication co-authored by CMRI’s Peptide Synthesis Facility’s Dr Md Musfizur Hassan, examined how nanoparticles can be used to predict the in vivo transport and drug delivery outcomes of various nanomedicine formulations across the blood brain barrier1. |
 Nanoparticles are small particles (1-100nm) that are used for different clinical applications as a dosage form of medicines. The nanosized colloidal particle has vesicles where therapeutics are loaded and after their widespread use for mRNA delivery in COVID-19 vaccines, lipid nanoparticles are the next big thing.The advantages of these nanoparticles are that they can encapsulate bigger/larger molecules like RNAs, DNAs, even whole genes, and they are biocompatible. |
| Nanoparticle research is in high demand for gene delivery and development of new gene therapies. Md Musfizur Hassan of the Peptide Synthesis Facility at Children’s Medical Research Institute has extensive expertise in nanoparticle synthesis, preparation, and characterisation. The facility can assist researchers by making nanoparticles with specific formulations, or by developing new formulations according to the researcher’s requirements. The facility works very collaboratively to achieve the best outcomes. Reach out to us (peptidesynthesis@cmri.org.au) if you are interested in nanoparticles, or other services which you can learn more about on our website. (1) https://pubs.acs.org/doi/abs/10.1021/acschemneuro.1c00538 |
posted on
Leave a Reply